Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 3310 for:    schizophrenia

Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04025502
Recruitment Status : Not yet recruiting
First Posted : July 19, 2019
Last Update Posted : July 23, 2019
Sponsor:
Collaborators:
COGNISION
Cadent Therapeutics
Alkermes, Inc.
Anavex Life Sciences Corp.
Merck Sharp & Dohme Corp.
Takeda
Sage Therapeutics
H. Lundbeck A/S
Information provided by (Responsible Party):
ERP Biomarker Qualification Consortium

Brief Summary:
This is an observational, non-interventional study that will recruit Healthy Volunteers (HV) and subjects with clinically confirmed Schizophrenia (SZ). The purpose of this study is to establish the mean and variance across the HV and SZ cohorts, sites, and repeated tests of the electroencephalogram(EEG)/Event-related potentials (ERP) measures.

Condition or disease Intervention/treatment
Schizophrenia Device: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System

Detailed Description:

Among the most replicated pathophysiological findings in schizophrenia is the impairment of Event-Related Potentials (ERPs) recorded during the auditory oddball procedure. In this procedure, time-locked electroencephalogram (EEG) responses are recorded during auditory processing of frequent and rare tones differing in pitch or duration. In addition, a smaller but substantial literature has reported deficits in the auditory steady-state EEG response (ASSR) to a 40 Hz train of auditory tones in subjects with schizophrenia versus healthy control subjects.

While measurement of ERPs in the drug development setting has shown promise, the instruments, infrastructure, and standardization of these methods has lagged. New, portable, easy-to-use, Food and Drug Administration (FDA)-approved devices are now available for the automated collection and analysis of EEG and ERP data.

This observational, non-interventional, clinical study will recruit healthy volunteer subjects (HV) and subjects with clinically confirmed schizophrenia (SZ), and will establish the mean and variance across HV and SZ cohorts, sites and repeated tests, of EEG and ERP measures collected with a standardized EEG/ERP device. The study will also examine the relationship between specific EEG/ERP features and measures of positive, negative, and cognitive symptoms and global function in SZ subjects.

The data collected in this study is intended to replicate published observations of the magnitude of deficit in ERPs in SZ versus HV subjects, and to support the design of subsequent interventional studies that will make use of ERPs. Furthermore, these data will be submitted to support qualification of the ERP biomarkers through the FDA Drug Development Tools Biomarker Qualification Program.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 160 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Multi-Center Study of Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects
Estimated Study Start Date : August 2019
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Group/Cohort Intervention/treatment
Healthy Volunteer Subjects (HV)

Male and female subjects 21-50 years of age, who are in good and stable health with no history or evidence of clinically relevant medical or neuropsychiatric illness.

Healthy Volunteer Subjects will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System.

Device: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System
The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.

Subjects with Schizophrenia (SZ)

Otherwise healthy male and female subjects 21-50 years of age, who have a current diagnosis of Schizophrenia with a duration of illness greater than or equal to one year.

Subjects with Schizophrenia (SZ) will undergo Event-Related Potential (ERP)/electroencephalogram (EEG) testing with the COGNISION® System.

Device: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System
The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.




Primary Outcome Measures :
  1. Amplitude (in microvolts) for parameters from the ERP tests. [ Time Frame: 12-18 months ]

    Amplitude (in microvolts) for the following parameters from the ERP tests will be collected as primary endpoints:

    1. Passive, Tone-deviant, Auditory Oddball ERP

      • N100
      • MMN
      • P3a
    2. Passive, Duration-deviant, Auditory Oddball ERP

      • N100
      • MMN
      • P3a
    3. Active, Auditory Oddball ERP

      • N100
      • P3b

  2. Latency (in milliseconds) for parameters from the ERP tests. [ Time Frame: 12-18 months ]

    Latency (in milliseconds) for the following parameters from the ERP tests will be collected as primary endpoints:

    1. Passive, Tone-deviant, Auditory Oddball ERP

      • N100
      • MMN
      • P3a
    2. Passive, Duration-deviant, Auditory Oddball ERP

      • N100
      • MMN
      • P3a
    3. Active, Auditory Oddball ERP

      • N100
      • P3b

  3. Task accuracy from the behavioral response during the active, auditory oddball ERP test. [ Time Frame: 12-18 months ]
    Task accuracy as a percentage of correct behavioral responses during the active, auditory oddball ERP test will be collected as a primary endpoint.

  4. Reaction time from the behavioral response during the active, auditory oddball ERP test. [ Time Frame: 12-18 months ]
    Reaction time for the correct behavioral responses to the test measured in milliseconds will be collected as a primary endpoint during the active, auditory oddball ERP test.

  5. Total Power from the auditory steady-state response (ASSR) paradigm. [ Time Frame: 12-18 months ]
    Total Power (measured in µv2/Hz) will be collected during the ASSR paradigm as a primary endpoint.

  6. Inter-trial coherence (ITC) from the auditory steady-state response (ASSR) paradigm. [ Time Frame: 12-18 months ]
    Inter-trial coherence (ITC) measured on a scale between 0 (no coherence) and 1 (maximum coherence) will be collected during the ASSR paradigm as a primary endpoint.

  7. Absolute Power for Pharmaco-EEG parameters per IPEG guidelines. [ Time Frame: 12-18 months ]

    Absolute Power (measured in µv2/Hz) will be collected from the Resting State EEG as a primary endpoint for the following Pharmaco-EEG parameters:

    • Delta power
    • Theta power
    • Alpha power
    • Beta power
    • Gamma power

  8. Relative Power for Pharmaco-EEG parameters per IPEG guidelines. [ Time Frame: 12-18 months ]

    Relative Power measured on a scale from 0 (no power in frequency band) to 1 (all EEG power in that frequency band) will be collected from the Resting State EEG as a primary endpoint for the following Pharmaco-EEG parameters:

    • Delta power
    • Theta power
    • Alpha power
    • Beta power

  9. Dominant frequency in the Alpha frequency band per IPEG guidelines [ Time Frame: 12-18 months ]
    Dominant frequency measured in Hz in the frequency interval between 6.0 and < 12.5 Hz will be collected from the Resting State EEG as a primary endpoint.

  10. Theta/Beta ratio and Slow Wave index per IPEG guidelines. [ Time Frame: 12-18 months ]
    Theta/Beta ratio and Slow Wave index (Alpha/Delta+Theta) measured in percentage will be collected from the Resting State EEG as primary endpoints.

  11. Functional assessments as derived from the Brief Assessment of Cognition in Schizophrenia (BACS). [ Time Frame: 12-18 months ]

    The following parameters will be collected for the BACS:

    BACS Variable Ranges Description Range Low Range High Unit Verbal Memory Total Score 0 75 n/a Digit Sequencing 0 28 n/a Token Motor Total Correct 0 100 n/a Verbal Fluency Total 0 100 n/a Symbol Coding 0 110 n/a Tower of London 0 22 n/a Verbal Memory T-Score -100 100 n/a Digit Sequencing T-Score -100 100 n/a Token Motor T-Score -100 100 n/a Verbal Fluency T-Score -100 100 n/a Symbol Coding T-Score -100 100 n/a Tower of London T-Score -100 100 n/a


  12. Functional assessments as derived from the Positive and Negative Symptom Scale for Schizophrenia (PANSS). [ Time Frame: 12-18 months ]

    The PANSS items are divided into three sections: Positive symptoms, negative symptoms, and general symptoms. The following parameters will be collected:

    PANSS Variable Ranges Description Range Low Range High Unit PANSS Items 1-30 1 7 n/a PANSS Total Score 30 210 n/a


  13. Functional assessments as derived from the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). [ Time Frame: 12-18 months ]

    The following parameters for the VRFCAT will be collected:

    VRFCAT Variable Ranges Description Range Low Range High Unit VRFCAT- Adjusted Total Time 0 60000 msec VRFCAT- Total Error Count 0 60 n/a VRFCAT- Total Forced Progressions 0 12 n/a Adjusted Total Time T-Score -100 100 n/a Total Errors T-Score -100 100 n/a Total Forced Progressions T-Score -100 100 n/a



Secondary Outcome Measures :
  1. Correlations between EEG/ERP measures and psychometric measures in Schizophrenia subjects. [ Time Frame: 12-18 months ]
    Pearson Correlation coefficients between EEG/ERP measures and scores from the functional assessments (BACS, PANSS, and VRFCAT) will be collected as secondary outcome measures.


Biospecimen Retention:   Samples Without DNA
Saliva drug screen to rule out illicit drug use for all three visits (Screening visit, Baseline visit, and Retest visit).


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

There will be four different sites where the participants will be selected in the following states: California, New Jersey, and New York.

Recruitment methods:

  • Database of individuals who have agreed to be contacted
  • Advertisements
  • Physician to physician referrals
Criteria
  • Inclusion Criteria for Healthy Volunteer Subjects (HV)

    • Healthy male and female subjects 21-50 years of age (inclusive).
    • Are not currently or have not participated in any other clinical studies within 30 days of Screening.
    • Ability to understand the requirements of the study, provide written informed consent, abide by the study procedures, and agree to return for the required assessments.
    • Subject is in good and stable health with no history or evidence of clinically relevant medical or neuropsychiatric illness.
    • Fluent in English, even if English is not the primary language. Subjects must hold a U.S. citizenship only for eligibility to participate.
  • Exclusion Criteria for Healthy Volunteer Subjects (HV)

    • Illicit drug use as determined by the saliva drug screen.
    • Current alcohol abuse as determined by the Investigator; or subject regularly consumed ≥3 alcoholic drinks/day during the 3 months prior to screening. One alcohol drink is approximately equivalent to: beer: 284 mL; wine: 125 mL (4 oz); or distilled spirits: 25 mL (1 oz).
    • Known (identifiable) biological family history of Schizophrenia spectrum disorders in a first or second degree relative.
    • Use of any first generation, sedating H1 antihistamines within 1 week prior to Screening or during the study. (see Medication Approval List)
    • Use of any sedative-hypnotic medications within 1 week prior to Screening or during the study. (see Medication Approval List)
    • Use of any other psychoactive medication known to interfere with ERP assessments within 1 week prior to Screening or during the study (see Medication Approval List).
    • Evidence or history of significant cognitive disorders, or other injuries, conditions, impairments, or situations that in the judgement of the Investigator would prevent safe and satisfactory completion of the study protocol.
    • Evidence or history of psychiatric illness as determined by the Mini International Neuropsychiatric Interview (MINI) for Psychotic Disorders.
    • Evidence of cognitive impairment as determined by performing ≥ 1.5 standard deviations lower compared to the age, sex, and education corrected mean on either the BACS Symbol Coding and/or Verbal Memory.
    • Significant intellectual disability as evidenced by a standardized WRAT-4 Reading Test standardized score < 70.
    • Unable to detect a 1000 and 2000 Hz tone at 40 dB in both ears.
    • Unable to tolerate the electrode cap for the duration of the testing session.
    • Known allergy to latex.
    • Use of products containing nicotine and/or caffeine 60 minutes prior to EEG/ERP testing.
  • Inclusion Criteria for Subjects with Schizophrenia (SZ)

    • Otherwise healthy male and female subjects 21-50 years of age (inclusive).
    • Are not currently or have not participated in any other clinical studies within 30 days of Screening.
    • Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.
    • Current diagnosis of schizophrenia.
    • Duration of schizophrenia illness ≥ 1 years.
    • Clinically stable and in the residual (non-acute) phase of their illness for at least 6 weeks prior to the study as evidenced by a stable medication regimen and no recent hospitalizations for acute Schizophrenia. The subject's clinical stability is ultimately up to the Investigator.
    • Maintained on a stable regimen of antipsychotic and/or permitted concomitant medications for at least 6 weeks prior to screening and during the study.
    • Subjects receiving treatment with up to 2, first or second-generation antipsychotics or other concomitant medications commonly prescribed to this patient population, may be included. (see Allowed Medications List)
    • Fluent in English, even if English is not the primary language. Subjects must hold a U.S. citizenship only for eligibility to participate.
  • Exclusion Criteria for Subjects with Schizophrenia (SZ)

    • Illicit drug use as evidenced by the saliva drug screen.
    • Current alcohol abuse as determined by the Investigator; or subject regularly consumed ≥3 alcoholic drinks/day during the 3 months prior to screening. One alcohol drink is approximately equivalent to: beer: 284 mL; wine: 125 mL (4 oz); or distilled spirits: 25 mL (1 oz).
    • Use of any first-generation, sedating H1 antihistamines within 1 week prior to Screening or during the study (see Medication Approval List).
    • Use of any sedative-hypnotic medications within 1 week prior to Screening or during the study. (see Medication Approval List)
    • Use of any other psychoactive medication known to interfere with ERP assessments within 1 week prior to Screening or during the study (see Allowed Medications List).
    • Evidence or history of significant cognitive disorders, or other injuries, conditions, impairments, or situations that in the judgement of the Investigator would prevent safe and satisfactory completion of the study protocol.
    • Failure to confirm a diagnosis of Schizophrenia by the Investigator.
    • Significant intellectual disability as evidenced by a standardized WRAT-4 Reading Test score < 70.
    • Have no more than a moderate severity rating on hallucinations and delusions as evidenced by a PANSS items P1 ≥ 4 and P3 ≥ 4.
    • Have no more than a moderate severity rating on positive formal thought disorder as evidenced by a PANSS items G9 ≥ 4 and P2 ≥ 4.
    • Presence of more than minimal extrapyramidal symptoms as evidenced by a SAS score > 6.
    • Presence of more than minimal level of depressive symptoms as evidenced by a CDSS score ≥ 10.
    • Unable to detect a 1000 and 2000 Hz tone at 40 dB in both ears.
    • Unable to tolerate the electrode cap for the duration of the testing session.
    • Known allergy to latex.
    • Use of products containing nicotine and/or caffeine 60 minutes prior to EEG/ERP testing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04025502


Contacts
Layout table for location contacts
Contact: Sarah N Martin, BSN 5025619040 ext 7014 smartin@cognision.com
Contact: Charlotte Hardesty, BSN 5025619040 ext 7003 chardesty@cognision.com

Sponsors and Collaborators
ERP Biomarker Qualification Consortium
COGNISION
Cadent Therapeutics
Alkermes, Inc.
Anavex Life Sciences Corp.
Merck Sharp & Dohme Corp.
Takeda
Sage Therapeutics
H. Lundbeck A/S
Investigators
Layout table for investigator information
Principal Investigator: Marco Cecchi, PhD ERP Biomarker Qualification Consortium

Publications:

Layout table for additonal information
Responsible Party: ERP Biomarker Qualification Consortium
ClinicalTrials.gov Identifier: NCT04025502     History of Changes
Other Study ID Numbers: EBS-A
First Posted: July 19, 2019    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ERP Biomarker Qualification Consortium:
ERP
EEG
Event-related potential
MMN
Schizophrenia
Electroencephalogram
Mismatch Negativity
N100
P3a
P3b
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders